New Data Show Durable Responses with Zenocutuzumab in NRG1 Fusion-Positive Cancers
CHICAGO – Updated results from the eNRGy trial, presented at the International Association for the Study of Lung Cancer (IASLC) and American Society of Clinical Oncology (ASCO) North American Conference on Lung Cancer (NACLC), demonstrate sustained anti-tumor activity with zenocutuzumab-zbco (BIZENGRI®) in patients with NRG1 fusion-positive non-small cell lung cancer (NSCLC).The data reinforce BIZENGRI as a potential new treatment option for this challenging-to-treat cancer subtype.
These findings are particularly significant as NRG1 fusions are relatively rare, occurring in approximately 1-2% of NSCLC cases, leaving patients with limited therapeutic choices. The eNRGy trial, a Phase 1/2 study, evaluated BIZENGRI in patients whose tumors harbor NRG1 fusions, a genetic alteration driving cancer growth. The updated analysis reveals durable responses and a manageable safety profile, offering hope for improved outcomes in this patient population. Partner Therapeutics, Inc. (PTx) holds exclusive rights to develop and commercialize zenocutuzumab-zbco in the U.S., and provides the product on a named-patient basis internationally.
The eNRGy trial data, published concurrently in the New England Journal of Medicine, showed an objective response rate of 27.3% among patients treated with zenocutuzumab-zbco. Median duration of response was not reached, indicating long-lasting benefits for responders. As of the data cutoff, patients were followed for up to 22.4 months.
BIZENGRI is a bispecific antibody designed to target NRG1, a protein often overexpressed in certain cancers. PTx’s portfolio also includes sargramostim (EU: IMREPLYS®; US: LEUKINE®; and with Nobelpharma Co. Ltd for JAPAN: SARGMALIN®).Further information, including full Prescribing Information and safety data, is available at https://www.bizengrihcp.com/pi.
Source: Partner Therapeutics,Inc.
